SG10201400388QA - IgE CH3 peptide vaccine - Google Patents

IgE CH3 peptide vaccine

Info

Publication number
SG10201400388QA
SG10201400388QA SG10201400388QA SG10201400388QA SG10201400388QA SG 10201400388Q A SG10201400388Q A SG 10201400388QA SG 10201400388Q A SG10201400388Q A SG 10201400388QA SG 10201400388Q A SG10201400388Q A SG 10201400388QA SG 10201400388Q A SG10201400388Q A SG 10201400388QA
Authority
SG
Singapore
Prior art keywords
ige
peptide vaccine
vaccine
peptide
Prior art date
Application number
SG10201400388QA
Other languages
English (en)
Inventor
Alan Daniel Brown
Brian Robert Champion
Clare Christy
David Paul Gervais
Lyn Howard Jones
Anne Maria Kristina Kjerrstrom
David Cameron Pryde
Lee Richard Roberts
David Michael Wyatt
Original Assignee
Pfizer Vaccines Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42035836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201400388Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Vaccines Llc filed Critical Pfizer Vaccines Llc
Publication of SG10201400388QA publication Critical patent/SG10201400388QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG10201400388QA 2008-12-09 2009-12-04 IgE CH3 peptide vaccine SG10201400388QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12098908P 2008-12-09 2008-12-09

Publications (1)

Publication Number Publication Date
SG10201400388QA true SG10201400388QA (en) 2014-05-29

Family

ID=42035836

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201400388QA SG10201400388QA (en) 2008-12-09 2009-12-04 IgE CH3 peptide vaccine
SG2012088373A SG186611A1 (en) 2008-12-09 2009-12-04 Ige ch3 peptide vaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2012088373A SG186611A1 (en) 2008-12-09 2009-12-04 Ige ch3 peptide vaccine

Country Status (21)

Country Link
US (3) US8298547B2 (https=)
EP (2) EP2376108B1 (https=)
JP (4) JP5209800B2 (https=)
KR (3) KR101634058B1 (https=)
CN (1) CN102245198B (https=)
AR (1) AR074505A1 (https=)
AU (1) AU2009325950B2 (https=)
BR (1) BRPI0922561A2 (https=)
CA (1) CA2744754A1 (https=)
CO (1) CO6561830A2 (https=)
DK (1) DK2376108T3 (https=)
ES (1) ES2622562T3 (https=)
IL (1) IL213029A0 (https=)
MX (2) MX2011006077A (https=)
NZ (2) NZ604186A (https=)
PE (2) PE20142330A1 (https=)
RU (1) RU2495049C2 (https=)
SG (2) SG10201400388QA (https=)
TW (1) TWI387463B (https=)
WO (1) WO2010067286A2 (https=)
ZA (1) ZA201104072B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101527334B1 (ko) * 2005-08-11 2015-06-09 알피 마토씨안-로저스 자가면역 질병의 치료 및 진단용 ｔｃｒ-ｖ-베타 관련 펩티드
SI2759306T1 (sl) * 2008-12-09 2016-05-31 Coley Pharmaceutical Group, Inc. Imunostimulacijski oligonukleotidi
EP2575868A1 (en) * 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
EP2471926A3 (en) 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
MX346596B (es) * 2011-05-26 2017-03-23 Intervet Int Bv Oligodesoxinucleotidos inmunoestimuladores.
PL2714908T3 (pl) * 2011-05-26 2018-07-31 Intervet International B.V. Oligodeoksynukleotydy immunostymulacyjne
WO2013110030A2 (en) 2012-01-19 2013-07-25 Duke University Vaccines against antigens involved in therapy resistance and methods of using same
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
EP2862873B1 (en) * 2012-06-18 2020-04-29 Nippon Zenyaku Kogyo Co., Ltd. IgE PEPTIDE VACCINE
CA2954279C (en) 2014-07-07 2023-11-14 Duke University Vaccines against an oncogenic isoform of esr1 and methods of using the same
EP3166646A4 (en) 2014-07-07 2018-03-07 Duke University Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same
CN107074925B (zh) 2014-07-10 2021-08-24 阿费里斯股份公司 用于预防和/或治疗亨廷顿氏病的物质和方法
RU2730871C1 (ru) * 2015-09-30 2020-08-26 Сионоги Энд Ко., Лтд. Производное нуклеиновой кислоты, обладающее иммуностимулирующей активностью
KR101876620B1 (ko) * 2015-10-27 2018-07-09 대구한의대학교산학협력단 펩타이드 기반 분자결합자를 이용한 노로바이러스 검출칩 및 그 제작방법
US11253580B2 (en) 2016-01-07 2022-02-22 Duke University Cancer vaccines and methods of delivery
KR102688761B1 (ko) 2016-03-03 2024-07-29 호유 가부시키가이샤 대두 알레르기의 항원
US10487143B2 (en) 2016-10-05 2019-11-26 Duke University Vaccines against HER3 antigens and methods of using the same
US11224665B2 (en) 2016-10-05 2022-01-18 Duke University Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same
SG11201908059YA (en) * 2017-03-29 2019-10-30 Shionogi & Co Nucleic acid derivative having immunostimulatory activity
US20230279143A1 (en) * 2020-08-13 2023-09-07 Nibec Co., Ltd. Protein comprising antibody for targeting oncogenic protein or single chain fragment variable thereof and cancer cell penetrating peptide, and use of the same
IL301402A (en) 2020-09-17 2023-05-01 Inst Nat Sante Rech Med IMMUNOGENIC PRODUCT COMPRISING AN IgE FRAGMENT FOR TREATING IgE-MEDIATED INFLAMMATORY DISORDERS
US20250205331A1 (en) * 2022-03-28 2025-06-26 The Regents Of The University Of California Novel plant virus and bacteriophage vaccines

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2055131B (en) 1978-09-29 1982-12-15 Energy Secretary Of State For Electrical power transmission in fluid wells
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
DE3280400D1 (de) 1981-10-23 1992-06-04 Molecular Biosystems Inc Oligonukleotides heilmittel und dessen herstellungsverfahren.
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
JPS63225397A (ja) * 1986-10-03 1988-09-20 Dainippon Pharmaceut Co Ltd 抗アレルギー作用を有する新規ペプチド
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5258289A (en) * 1990-09-05 1993-11-02 Davis Claude G Method for the selecting of genes encoding catalytic antibodies
EP0563091A1 (en) 1990-12-20 1993-10-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccines based on hepatitis b surface antigen
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
DE4321946A1 (de) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5658738A (en) 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
CN1185811A (zh) 1995-03-31 1998-06-24 H·沃尔夫 依赖于逆转录病毒样颗粒的抗原呈递系统
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
CA2245497C (en) 1996-03-01 2009-02-24 Novartis Ag Peptide immunogens for vaccination against and treatment of allergy
ID18046A (id) 1996-08-20 1998-02-19 Takeda Chemical Industries Ltd Senyawa siklik campuran, pembuatan dan penngunaannya.
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
AUPO517897A0 (en) * 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
EP1003850B1 (en) 1997-06-06 2009-05-27 The Regents of the University of California Inhibitors of dna immunostimulatory sequence activity
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
CZ302092B6 (cs) 1998-02-12 2010-10-06 Immune Complex, Corporation Konjugát upraveného jaderného proteinu hepatitidy B, jeho cástice, inokulum a zpusob indukce protilátek
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
AU760549B2 (en) 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
DE69922873T2 (de) * 1998-04-09 2005-12-29 Idexx Laboratories, Inc. Spezifische Bindungsproteine zur Behandlung von Allergien beim Hund
US6734287B1 (en) * 1998-04-09 2004-05-11 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
US7393529B2 (en) * 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
EP2123292B1 (en) 1998-09-03 2016-05-04 Novartis Vaccines and Diagnostics, Inc. Angiogenically effective unit dose of FGF-2 and method of use
AU9059798A (en) 1998-09-18 2000-04-10 Pentapharm Ag Urokinase inhibitors
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
DE69929232T2 (de) 1998-10-21 2006-08-31 The United States Government As Represented By The Department Of Health And Human Services Virusähnliche partikel zur induktion von autoantikörpern
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
ES2257879T3 (es) 1998-11-05 2006-08-01 Powderject Vaccines, Inc. Productos de recombinacion de acido nucleico para inmunizacion genetica.
MXPA01005389A (es) 1998-11-30 2003-03-27 Cytos Biotechnology Ag Presentacion molecular ordenada de antigenos, metodos de preparacion y uso.
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
ES2572834T3 (es) 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
US20030170229A1 (en) * 1999-02-25 2003-09-11 Smithkline Beecham Biologicals S.A. Vaccine
EP1155038A1 (en) 1999-02-25 2001-11-21 SMITHKLINE BEECHAM BIOLOGICALS (S.A.), formerly SMITHKLINE BIOLOGICALS (S.A.) Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses
ATE459373T1 (de) 1999-03-19 2010-03-15 Glaxosmithkline Biolog Sa Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
JP2002539818A (ja) * 1999-03-30 2002-11-26 アイデックス ラボラトリーズ インコーポレイテッド イヌのアレルギーを治療するための特異的結合蛋白
PT1187629E (pt) 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
HUP0202885A3 (en) 1999-09-24 2004-07-28 Smithkline Beecham Biolog Vaccines
TR200200777T2 (tr) 1999-09-24 2002-09-23 Smithkline Beecham Biologicals S.A. Polioksietilen alkil eteri veya esteriyle en az bir iyonik olmayan yüzey aktif maddeli adjuvant.
AU783118B2 (en) 1999-09-27 2005-09-29 Coley Pharmaceutical Gmbh Methods related to immunostimulatory nucleic acid-induced interferon
DE60122300T2 (de) 2000-04-07 2007-08-30 The University Of Leeds Hepatitis b kernprotein fusionsproteine
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
AU2001266163B2 (en) 2000-06-22 2006-07-13 Celltech Pharmaceticals Limited Modification of hepatitis b core antigen
AU2001269272A1 (en) 2000-07-15 2002-01-30 Lighthouse Display International Limited Shelf edge display fittings
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
EP1195161A3 (en) * 2000-08-30 2002-07-24 Pfizer Products Inc. Anti-IgE vaccines
GB0026334D0 (en) 2000-10-27 2000-12-13 Smithkline Beecham Biolog Vaccine
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
WO2003102165A2 (en) 2002-02-21 2003-12-11 Apovia, Inc. IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
CA2492823A1 (en) 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
US20040176283A1 (en) * 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
GB0209878D0 (en) 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
CU22983A1 (es) * 2002-05-08 2004-09-09 Inst Finlay Composición vacunal contra las alergias y método para su obtención y empleo en el tratamiento de las mismas
US7138252B2 (en) 2002-07-17 2006-11-21 Cytos Biotechnology Ag Molecular antigen arrays
AU2003300841B2 (en) 2002-12-10 2008-03-20 Lorantis Ltd. Stabilized immunogenic HBc chimer particles
AU2004224761A1 (en) * 2003-03-26 2004-10-07 Cytos Biotechnology Ag HIV-peptide-carrier-conjugates
CN102702359A (zh) 2004-02-02 2012-10-03 泰勒公司 新的IgE表位的鉴别
EP1776105A2 (en) 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
US20060287263A1 (en) 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing antigen-specific immune responses
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
US20090087456A1 (en) * 2005-09-07 2009-04-02 James Edward Eyles Adjuvanted vaccine
DK2405002T3 (en) 2006-02-15 2015-01-05 Adiutide Pharmaceuticals Gmbh Compositions and methods for oligonukleotidformuleringer
US20080166785A1 (en) 2006-08-16 2008-07-10 Monica Sala-Schaeffer Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use
JP2010532158A (ja) 2007-04-02 2010-10-07 アムジェン フレモント インク． 抗ＩｇＥ抗体
ES2602610T3 (es) * 2007-05-31 2017-02-21 Medigene Ag Proteína estructural mutada de un parvovirus
US9501570B2 (en) 2014-07-14 2016-11-22 Verizon Patent And Licensing Inc. Dynamic routing system
US9719791B2 (en) 2014-12-10 2017-08-01 Mapquest, Inc. Computerized systems and methods for providing travel information and/or content to users
JP6911110B2 (ja) 2016-06-23 2021-07-28 リップルズ エルティーディー．Ｒｉｐｐｌｅｓ Ｌｔｄ． 飲料上に印刷するための方法及び装置

Also Published As

Publication number Publication date
US8298547B2 (en) 2012-10-30
KR101413844B1 (ko) 2014-06-30
KR20150056881A (ko) 2015-05-27
KR20110094134A (ko) 2011-08-19
US8475801B2 (en) 2013-07-02
JP2012511322A (ja) 2012-05-24
AR074505A1 (es) 2011-01-19
ZA201104072B (en) 2012-02-29
JP5367137B2 (ja) 2013-12-11
RU2011121043A (ru) 2013-01-20
MX2011006077A (es) 2011-09-01
EP2376108B1 (en) 2017-02-22
EP2865389A1 (en) 2015-04-29
CA2744754A1 (en) 2010-06-17
WO2010067286A2 (en) 2010-06-17
AU2009325950B2 (en) 2013-03-07
SG186611A1 (en) 2013-01-30
CN102245198B (zh) 2016-08-17
RU2495049C2 (ru) 2013-10-10
JP2014012009A (ja) 2014-01-23
TW201036632A (en) 2010-10-16
BRPI0922561A2 (pt) 2020-08-11
NZ592977A (en) 2013-01-25
HK1163511A1 (zh) 2012-09-14
JP2016164156A (ja) 2016-09-08
US20120294848A1 (en) 2012-11-22
JP5964280B2 (ja) 2016-08-03
EP2376108A2 (en) 2011-10-19
NZ604186A (en) 2014-07-25
CN102245198A (zh) 2011-11-16
US9216229B2 (en) 2015-12-22
DK2376108T3 (en) 2017-04-24
AU2009325950A1 (en) 2010-06-17
WO2010067286A3 (en) 2010-08-05
PE20110891A1 (es) 2011-12-23
JP2012255006A (ja) 2012-12-27
JP5209800B2 (ja) 2013-06-12
ES2622562T3 (es) 2017-07-06
TWI387463B (zh) 2013-03-01
KR101634058B1 (ko) 2016-06-27
IL213029A0 (en) 2011-07-31
US20100158933A1 (en) 2010-06-24
US20140017239A1 (en) 2014-01-16
MX337723B (es) 2016-03-15
CO6561830A2 (es) 2012-11-15
KR20130032390A (ko) 2013-04-01
PE20142330A1 (es) 2015-01-14
KR101644221B1 (ko) 2016-07-29

Similar Documents

Publication Publication Date Title
ZA201104072B (en) Ige ch3 peptide vaccine
IL219048A (en) Peptide compounds derived from urcl10
ZA201101481B (en) Vaccine
IL208660A0 (en) Coccididosis vaccines
IL208651A0 (en) Vaccine
GB0822001D0 (en) Vaccine
GB0810710D0 (en) Vaccine
IL214257A0 (en) Peptides for vaccine
ZA201007402B (en) Vaccine
GB0920981D0 (en) Peptides
IL199622A0 (en) Foxp3 peptide vaccine
GB0816447D0 (en) Vaccine
GB0816284D0 (en) Vaccine
ZA201108446B (en) FViII-DERIVED PEPTIDES
GB0801326D0 (en) Vaccines
GB0920987D0 (en) Peptides
GB0817978D0 (en) Peptides
GB0815674D0 (en) Nematode vaccine
GB0810449D0 (en) Peptides
GB0812093D0 (en) Phylloseptin peptides
GB0815673D0 (en) Peptides
GB0810914D0 (en) Vaccine
GB0802108D0 (en) Vaccine
GB0820478D0 (en) Vaccine
GB0810215D0 (en) Vaccine